deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT03792555

A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve)

A Double-blind, Placebo-controlled, Randomized Withdrawal Study to Evaluate the Safety, Pharmacokinetics and Efficacy of CRN00808 in Patients With Acromegaly That Are Responders to Octreotide LAR or Lanreotide Depot (ACROBAT Evolve)

Sponsor: Crinetics Pharmaceuticals Inc.

Conditions Acromegaly
Interventions Paltusotine Placebo
Updated 17 times since 2019 Last updated: Mar 4, 2025 Started: Mar 11, 2019 Primary completion: Jul 15, 2020 Completion: Aug 12, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Acromegaly and is currently completed. Crinetics Pharmaceuticals Inc. leads this study, which shows 17 recorded versions since 2019 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Jul 2019 · 2 months · monthly snapshot~Jul 2019 – ~Sep 2019 · 2 months · monthly snapshot~Sep 2019 – ~Dec 2019 · 3 months · monthly snapshot~Dec 2019 – ~Feb 2020 · 2 months · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Jun 2020 · 3 months · monthly snapshot~Jun 2020 – ~Dec 2020 · 6 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Apr 2022 · 7 months · monthly snapshot~Apr 2022 – ~Jul 2024 · 27 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Apr 2025 · 7 months · monthly snapshot~Apr 2025 – present · 14 months · monthly snapshot

Change History

17 versions recorded

  1. Apr 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Apr 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Apr 2022 — Jul 2024 [monthly]

    Completed PHASE2

  5. Sep 2021 — Apr 2022 [monthly]

    Completed PHASE2

▶ Show 12 earlier versions

  1. Jan 2021 — Sep 2021 [monthly]

    Completed PHASE2

  2. Dec 2020 — Jan 2021 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  3. Jun 2020 — Dec 2020 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Mar 2020 — Jun 2020 [monthly]

    Recruiting PHASE2

  5. Feb 2020 — Mar 2020 [monthly]

    Recruiting PHASE2

  6. Dec 2019 — Feb 2020 [monthly]

    Recruiting PHASE2

  7. Sep 2019 — Dec 2019 [monthly]

    Recruiting PHASE2

  8. Jul 2019 — Sep 2019 [monthly]

    Recruiting PHASE2

  9. May 2019 — Jul 2019 [monthly]

    Recruiting PHASE2

  10. Apr 2019 — May 2019 [monthly]

    Recruiting PHASE2

  11. Mar 2019 — Apr 2019 [monthly]

    Recruiting PHASE2

  12. Feb 2019 — Mar 2019 [monthly]

    Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Crinetics Pharmaceuticals Inc.
Data source: Crinetics Pharmaceuticals Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Athens, Greece , Belgrade, Serbia , Budapest, Hungary , Columbus, United States , Curitiba, Brazil , Dallas, United States , Pécs, Hungary , São Paulo, Brazil , Warsaw, Poland , Wellington, New Zealand and 1 more location